Annexin Pharmaceuticals: Comment on rights issue and recent newsflow - Redeye
Redeye comments on the terms in Annexin’s rights issue and recent newsflow, which includes updates from the ANXV NEXUS study and an interesting deal in the sector.
ANNONS
Redeye comments on the terms in Annexin’s rights issue and recent newsflow, which includes updates from the ANXV NEXUS study and an interesting deal in the sector.
